PE is a life-threatening condition for the mother, the fetus, and the newborn. MMP participates in the two primary stages of PE: remodeling of blood vessels at the placental formation and hypertension development location due to damage to blood vessels’ basement membrane. The present study’s object was to reveal the role of MMP-2 and MMP-9 in the development of severe preeclampsia. 

We conducted a retrospective study that included 92 pregnant women at a gestational age of 26-38 weeks, of which the principal group consisted of 61 patients with severe PE. 

In the group of PE patients with both EO-PE and LO-PE, the level of MMP-2 was significantly higher compared to the women undergoing normal pregnancy; and we observed no significant differences when we reached the levels of MMP-2 in the subgroups with EO-PE and LO-PE. Analysis of the concentrations of MMP-9 in EO-PE and LO-PE subgroups revealed attenuated levels of MMP-9 in both groups relative to the control group. We also noted a diminished level of MMP-9 in the EO-PE group compared to the LO-PE group. 

The study concluded that the significantly increased levels of MMP-2 in women—both in the EO-PE and LO severe PE subgroups—explain the participation of this enzyme in endothelial dysfunction in the second stage of severe PE.